Publications
- 10 years of experience with thalidomide in multiple myeloma patients: Report of the Czech Myeloma Group2013 | Central Library of Charles University
- Persistent Overall Survival Benefit and No Increased Risk of Second Malignancies With Bortezomib-Melphalan-Prednisone Versus Melphalan-Prednisone in Patients With Previously Untreated Multiple Myeloma2013 | First Faculty of Medicine
- Randomized Phase II Study of Bortezomib, Thalidomide, and Dexamethasone With or Without Cyclophosphamide As Induction Therapy in Previously Untreated Multiple Myeloma2013 | First Faculty of Medicine
- Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma2013 | First Faculty of Medicine
- Complex karyotype and translocation t(4;14) define patients with high-risk newly diagnosed multiple myeloma: results of CMG2002 trial +12012 | First Faculty of Medicine
- Continuous lenalidomide treatment for newly diagnosed multiple myeloma2012 | First Faculty of Medicine
- Treatment of multiple myeloma with lenalidomide in 20122012 | First Faculty of Medicine
- Lenalidomide in the first and additional lines of therapy for multiple myeloma2012 | First Faculty of Medicine
- Intrapleural Bortezomib for the Therapy of Myelomatous Pleural Effusion: A Case Report2012 | First Faculty of Medicine
- Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma2011 | First Faculty of Medicine
Loading network view...